Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of Prior Exposure to Conflicting Health Information on Responses to Subsequent Unrelated Health Messages

9 novembre 2020 aggiornato da: University of Minnesota
Many population-level public health strategies-including media campaigns and other behavioral interventions, screening recommendations, and vaccination policies-rely on messaging to promote cancer prevention and control. These strategies do not take place in a vacuum; rather, they occur in the context of a broader public information environment, which is increasingly characterized by conflicting and often controversial health information. Although studies have documented that such information is prevalent, a critical question remains unanswered: does exposure to conflicting health information in people's routine interactions with the broader information environment threaten the success of message-based population-level public health strategies? And, if so, who is most susceptible to the effects of such exposure? This study will provide a rigorous empirical test of these critical answered questions, guided by two specific aims: First, to evaluate whether prior exposure to conflicting health information influences responses to subsequent unrelated and uncontested health messages, a phenomenon that has been described as "carryover effects" (Primary Aim); and second, to identify whether there are individual-level differences in how conflict affects responses to these unrelated and uncontested health messages (Secondary Aim).

Panoramica dello studio

Descrizione dettagliata

To accomplish these aims, an online survey-based experiment using a population-based sample of U.S. adults (anticipated N=1,800) will be conducted. At 2 time points across a 28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants will be randomized to 1 of 2 treatment groups that differ only in the amount of conflict presented in these news and social media posts (conflict, no conflict). At a third time point, after the exposure to conflict period, all participants will be exposed to 3 (out of a possible 9) messages from existing health campaigns about 3 behaviors for which there is scientific consensus: fruit and vegetable consumption, colorectal cancer screening, and physical activity. To assess carryover effects (Primary Aim), participants' receptivity to these messages-as measured through several affective and cognitive responses (e.g., confidence in the evidence presented)-will be measured. Message receptivity is expected to be lower among those who were randomized to receive conflicting health information. Individual-level differences in message receptivity are possible; thus exploratory analyses (Secondary Aim) will be conducted to assess whether carryover effects of exposure to conflict may be more pronounced among certain groups (e.g., those with greater trust in media sources, those of lower socioeconomic position).

Tipo di studio

Interventistico

Iscrizione (Effettivo)

6046

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Illinois
      • Chicago, Illinois, Stati Uniti, 60603
        • NORC at the University of Chicago (online only)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 18+ U.S. adults
  • Members of NORC's AmeriSpeak Panel (https://amerispeak.norc.org/Pages/default.aspx)
  • Able to complete web-based survey
  • Able to read in English

Exclusion Criteria:

  • None

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: No exposure to conflict
At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
Sperimentale: Exposure to conflict
At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Negative affective responses
Lasso di tempo: Up to 42 days
  • Participants are asked to indicate how "the ad you just saw made you feel"
  • 7 affective responses are randomly ordered: interested, frustrated, surprised, annoyed, distressed, optimistic, worried (response options: 1 "very slightly or not at all" to 5 "extremely")
Up to 42 days
Counterarguing
Lasso di tempo: Up to 42 days

• Participants are asked to indicate the extent to which they agree or disagree with 4 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):

  • "I found myself agreeing with the ad" (reverse coded)
  • "I thought of points that went against what the ad was saying"
  • "I accepted the ad's claims" (reverse coded)
  • "While reading the ad, I was skeptical of its claims"
Up to 42 days
Reactance/threat to freedom
Lasso di tempo: Up to 42 days
• Participants are asked to indicate the extent to which they agree or disagree with the following statement (response options: 1 "strongly disagree" to 5 "strongly agree"): "I felt like the ad was trying to manipulate me"
Up to 42 days
Other negative cognitive responses to ad claims
Lasso di tempo: Up to 42 days
• Participants are asked to indicate whether "the claims in the ad I just saw are" (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"): exaggerated, flawed, believable (reverse coded), reasonable (reverse coded)
Up to 42 days
Perceived argument strength
Lasso di tempo: Up to 42 days

• Participants are asked to indicate the extent to which they agree or disagree with 2 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):

  • "The ad was convincing"
  • "The ad gave me a strong reason to [engage in the behavior specified in the ad]"
Up to 42 days
Response efficacy
Lasso di tempo: Up to 42 days

• Participants are asked to respond to two items, presented in random order:

  • "How confident are you that there is evidence to support the ad's claims?" (1 "not confident at all" to 7 "extremely confident")
  • "How much do you think your health would benefit if you [engaged in the behavior specified in the ad]?" (1 "not at all" to 7 "extremely")
Up to 42 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 luglio 2020

Completamento primario (Effettivo)

31 agosto 2020

Completamento dello studio (Effettivo)

31 agosto 2020

Date di iscrizione allo studio

Primo inviato

16 gennaio 2020

Primo inviato che soddisfa i criteri di controllo qualità

27 gennaio 2020

Primo Inserito (Effettivo)

30 gennaio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2020

Ultimo verificato

1 novembre 2020

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2019NTLS140
  • R21CA218054 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Descrizione del piano IPD

Within one year of study completion, the final, cleaned, de-identified study dataset may be made available to third-party users under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes; 2) a commitment to securing the data using appropriate information technology; and 3) a commitment to destroying or returning the data after analyses are completed. Requests for data sharing will be considered by the investigator team via in-person meetings and approved by consensus; meeting minutes will be taken to ensure transparent decision making and conflict of interest avoidance.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi